Diamedica Therapeutics Stock Performance
| DMAC Stock | USD 7.95 0.28 3.40% |
The firm shows a Beta (market volatility) of 1.51, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, DiaMedica Therapeutics will likely underperform. At this point, DiaMedica Therapeutics has a negative expected return of -0.055%. Please make sure to confirm DiaMedica Therapeutics' mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to decide if DiaMedica Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weak
Weak | Strong |
Over the last 90 days DiaMedica Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, DiaMedica Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return (2.14) | Five Day Return (10.06) | Year To Date Return (1.89) | Ten Year Return 250.45 | All Time Return (81.06) |
Last Split Factor 1:20 | Dividend Date 2018-11-15 | Last Split Date 2018-11-15 |
1 | DiaMedica Therapeutics Trading Up 7.4 percent Heres Why | 12/12/2025 |
2 | Heres Why Were Not Too Worried About DiaMedica Therapeutics Cash Burn Situation | 12/18/2025 |
3 | Acquisition by Semba Charles Pauling of 3355 shares of DiaMedica Therapeutics at 8.42 subject to Rule 16b-3 | 01/02/2026 |
4 | Acquisition by Giuffre Randall Michael of 32162 shares of DiaMedica Therapeutics at 4.11 subject to Rule 16b-3 | 01/06/2026 |
5 | What technical charts say about DiaMedica Therapeutics Inc. stock - July 2025 Action Free Weekly Watchlist of Top Performers - ulpravda.ru | 01/08/2026 |
6 | Acquisition by Parsons James T. of 4287 shares of DiaMedica Therapeutics at 5.51 subject to Rule 16b-3 | 01/12/2026 |
7 | DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 01/16/2026 |
8 | Cantor Fitzgerald Sticks to Its Buy Rating for Diamedica Therapeutics - The Globe and Mail | 01/23/2026 |
9 | DiaMedica Therapeutics Strengthens Balance Sheet with 12.2 Million Capital Raise While Advancing Preeclampsia Program | 02/06/2026 |
10 | Is DiaMedica Therapeutics Inc. stock a top performer YTD - July 2025 Volume AI Enhanced Trading Alerts - mfd.ru | 02/12/2026 |
11 | DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences | 02/24/2026 |
| Begin Period Cash Flow | 4.5 M | |
| Total Cashflows From Investing Activities | 8.6 M |
DiaMedica | Build AI portfolio with DiaMedica Stock |
DiaMedica Therapeutics Relative Risk vs. Return Landscape
If you would invest 851.00 in DiaMedica Therapeutics on December 3, 2025 and sell it today you would lose (56.00) from holding DiaMedica Therapeutics or give up 6.58% of portfolio value over 90 days. DiaMedica Therapeutics is currently does not generate positive expected returns and assumes 3.4262% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than DiaMedica, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DiaMedica Therapeutics Target Price Odds to finish over Current Price
The tendency of DiaMedica Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.95 | 90 days | 7.95 | about 86.97 |
Based on a normal probability distribution, the odds of DiaMedica Therapeutics to move above the current price in 90 days from now is about 86.97 (This DiaMedica Therapeutics probability density function shows the probability of DiaMedica Stock to fall within a particular range of prices over 90 days) .
DiaMedica Therapeutics Price Density |
| Price |
Predictive Modules for DiaMedica Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as DiaMedica Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.DiaMedica Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. DiaMedica Therapeutics is not an exception. The market had few large corrections towards the DiaMedica Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold DiaMedica Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of DiaMedica Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.02 | |
β | Beta against Dow Jones | 1.51 | |
σ | Overall volatility | 0.40 | |
Ir | Information ratio | 0.01 |
DiaMedica Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of DiaMedica Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for DiaMedica Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| DiaMedica Therapeutics generated a negative expected return over the last 90 days | |
| DiaMedica Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (24.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 29.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences |
DiaMedica Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of DiaMedica Stock often depends not only on the future outlook of the current and potential DiaMedica Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. DiaMedica Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40.4 M | |
| Cash And Short Term Investments | 44.1 M |
DiaMedica Therapeutics Fundamentals Growth
DiaMedica Stock prices reflect investors' perceptions of the future prospects and financial health of DiaMedica Therapeutics, and DiaMedica Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DiaMedica Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 358.44 M | ||||
| Shares Outstanding | 52.08 M | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 8.01 X | ||||
| EBITDA | (26.64 M) | ||||
| Net Income | (24.44 M) | ||||
| Cash And Equivalents | 38.44 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 340 K | ||||
| Current Ratio | 25.50 X | ||||
| Book Value Per Share | 0.99 X | ||||
| Cash Flow From Operations | (22.08 M) | ||||
| Earnings Per Share | (0.71) X | ||||
| Market Capitalization | 414.02 M | ||||
| Total Asset | 46.34 M | ||||
| Retained Earnings | (140 M) | ||||
| Working Capital | 39.22 M | ||||
| Current Asset | 5.24 M | ||||
| Current Liabilities | 1.05 M | ||||
About DiaMedica Therapeutics Performance
By analyzing DiaMedica Therapeutics' fundamental ratios, stakeholders can gain valuable insights into DiaMedica Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if DiaMedica Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if DiaMedica Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.09 | 0.08 | |
| Return On Tangible Assets | (0.47) | (0.50) | |
| Return On Capital Employed | (0.75) | (0.79) | |
| Return On Assets | (0.47) | (0.50) | |
| Return On Equity | (0.54) | (0.57) |
Things to note about DiaMedica Therapeutics performance evaluation
Checking the ongoing alerts about DiaMedica Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DiaMedica Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DiaMedica Therapeutics generated a negative expected return over the last 90 days | |
| DiaMedica Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (24.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 29.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences |
- Analyzing DiaMedica Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DiaMedica Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining DiaMedica Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DiaMedica Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of DiaMedica Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DiaMedica Therapeutics' stock. These opinions can provide insight into DiaMedica Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |